Vyxeos is a drug owned by Jazz Pharmaceuticals Therapeutics Inc. It is protected by 9 US drug patents filed from 2017 to 2021. Out of these, 8 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 15, 2032. Details of Vyxeos's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vyxeos's patents.

Latest Legal Activities on Vyxeos's Patents

Given below is the list of recent legal activities going on the following patents of Vyxeos.

Activity	Date	Patent Number
Legal Activities for all Patents
Payment of Maintenance Fee, 4th Year, Large Entity	01 May, 2024	US10835492
Payment of Maintenance Fee, 12th Year, Large Entity	28 Jun, 2023	US8092828
Payment of Maintenance Fee, 12th Year, Large Entity	08 Mar, 2023	US8022279
Correspondence Address Change Critical	07 Mar, 2023	US8518437
Correspondence Address Change Critical	27 Feb, 2023	US8431806
Correspondence Address Change Critical	27 Feb, 2023	US8092828
Email Notification Critical	03 Jan, 2023	US10835492
Change in Power of Attorney (May Include Associate POA) Critical	03 Jan, 2023	US10028912
Change in Power of Attorney (May Include Associate POA) Critical	03 Jan, 2023	US8092828
Email Notification Critical	03 Jan, 2023	US10166184

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Vyxeos and ongoing litigations to help you estimate the early arrival of Vyxeos generic.

Vyxeos's Litigations

Vyxeos been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 06, 2010, against patent number US8518437. The petitioner , challenged the validity of this patent, with Paul Tardi et al as the respondent. Click below to track the latest information on how companies are challenging Vyxeos's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US9271931	October, 2012	Decision (31 Aug, 2015)	Paul Tardi et al
US8518437	December, 2010	Decision (05 Mar, 2013)	Paul Tardi et al

FDA has granted some exclusivities to Vyxeos. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vyxeos, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vyxeos.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Vyxeos's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Vyxeos's generic, the next section provides detailed information on ongoing and past EP oppositions related to Vyxeos patents.

Vyxeos's Oppositions Filed in EPO

Vyxeos has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 15, 2018, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP08730048A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP17200498A	Oct, 2022	Generics [UK] Limited	Granted and Under Opposition
EP17200498A	Oct, 2022	SANDOZ AG	Granted and Under Opposition
EP17200498A	Oct, 2022	STADA Arzneimittel AG	Granted and Under Opposition
EP12841616A	Apr, 2020	D Young & Co LLP	Granted and Under Opposition
EP12841616A	Apr, 2020	SANDOZ AG	Granted and Under Opposition
EP08730048A	Aug, 2018	Generics (U.K.) Limited	Revoked
EP08730048A	Aug, 2018	Teva Pharmaceutical Industries Ltd	Revoked

US patents provide insights into the exclusivity only within the United States, but Vyxeos is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vyxeos's family patents as well as insights into ongoing legal events on those patents.

Vyxeos's Family Patents

Vyxeos has patent protection in a total of 25 countries. It's US patent count contributes only to 27.5% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Vyxeos.

Unlock Global Patents

Generic Launch

About Vyxeos

Vyxeos is a drug owned by Jazz Pharmaceuticals Therapeutics Inc. It is used for treating newly-diagnosed therapy-related acute myeloid leukemia (T-AML) or AML with myelodysplasia-related changes (AML-MRC) in children and adults. Vyxeos uses Cytarabine; Daunorubicin as an active ingredient. Vyxeos was launched by Jazz Pharms Therap in 2017.